RemeGen Co. Ltd. Class A
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jian Min Fang
- Full Time Employees
- 3,048
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 58 Middle Beijing Road Yantai SD China 411100
- IPO Date
- Nov 9, 2020
- Website
- remegen.com
- Similar Companies
- Business
- RemeGen Co., Ltd. (688331.SS) is a biopharmaceutical company that discovers, develops, produces, and commercializes innovative biological drugs targeting autoimmune diseases, oncology, and ophthalmic disorders. The company offers Telitacicept (RC18, trade name: Tai'ai), the world's first BLyS/APRIL dual-target fusion protein approved in China for systemic lupus erythematosus, rheumatoid arthritis, generalized myasthenia gravis, and primary Sjögren's syndrome; Disitamab Vedotin (RC48, trade name: Aidixi), China's first independently developed HER2-targeting antibody-drug conjugate (ADC) approved for gastric cancer, urothelial carcinoma, and breast cancer; and RC28-E, an ophthalmic biologic in Phase III trials for diabetic macular edema and wet age-related macular degeneration. Its pipeline includes additional candidates such as RC108, RC118, RC138, RC148 (a bispecific antibody advancing to Phase II in the U.S.), RC158, RC198, RC218, RC228, and RC278, addressing solid tumors, non-small cell lung cancer, and ophthalmopathy. RemeGen operates primarily in China and the United States, with research laboratories, manufacturing facilities, and offices in both regions. Founded in 2008 and headquartered in Yantai, Shandong Province, China, RemeGen focuses on first-in-class and best-in-class therapeutics, including antibody-drug conjugates, fusion proteins, monoclonal antibodies, and bispecific antibodies. The company serves patients and healthcare providers through its commercial infrastructure in domestic and international markets, with revenue predominantly from China. Recent developments include an exclusive global licensing agreement in June 2025 with Vor Bio for ex-Greater China rights to Telitacicept, featuring a $125 million initial payment, up to $4 billion in milestones, and tiered royalties; and an August 2025 exclusive licensing deal with Santen Pharmaceutical for RC28-E in Greater China and select Asian countries. Additional milestones encompass U.S. FDA clearance in August 2025 for Phase II trials of RC148; positive Phase III topline results for Telitacicept in primary Sjögren's syndrome in August 2025; and key presentations at ESMO 2025 and ASCO 2025 highlighting Disitamab Vedotin's efficacy in first-line urothelial carcinoma and gastric cancer. These advances support RemeGen's global expansion and pipeline progression.
Company News
AbbVie, RemeGen partner on experimental solid tumor treatment
Short Interest in RemeGen Co., Ltd. (OTCMKTS:REGMF) Drops By 45.0%
RemeGen (OTCMKTS:REGMF) Trading Down 7.7% – Should You Sell?
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA
PureTech Founded Entity Vor Bio Announces Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset and $175 Million Private Placement
RemeGen's Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis
RemeGen: Telitacicept for the Treatment of Generalized Myasthenia Gravis Approved in China
Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis